Summary of the Conference Call for Yijiahe Group Company Overview - Yijiahe Group operates through its subsidiary Tuodao Medical, focusing on brain-computer interface (BCI) technology and surgical robotics, with applications in healthcare and industrial sectors [2][3] Core Business Segments - The company’s business includes energy, surgical robots, commercial cleaning, and military humanoid robots [2][3] - Tuodao Medical is developing automated implantation technology for invasive BCIs and surgical robots, aiming to enhance the quality of life for individuals and expand applications in various work environments [2][3] Technological Accumulation - Tuodao Medical has made significant advancements in: 1. **Invasive Brain-Computer Interfaces**: Capable of capturing high-precision electrophysiological signals for complex control [5] 2. **Stereotactic Technology**: Transitioning from traditional frameworks to surgical robots to improve precision and reduce errors [5] 3. **Development of Domestic Surgical Robots**: Companies like Huazhi Weichuang and Baihui Yikang have introduced new products, expanding the range of applications and improving clinical outcomes [5][6] 4. **Application Processes**: Emphasizing precise positioning during invasive electrode implantation to minimize trauma and enhance success rates [5] Market Dynamics - The domestic market for neurosurgical robots is rapidly evolving, with leading companies like Huazhi Weichuang and Baihui Yikang replacing imported products, indicating strong domestic competitiveness [6] - The market has seen a shift from larger, complex systems to more compact and stable solutions, reflecting changing clinical needs [9] Importance of Surgical Robots - Surgical robots are essential for BCI procedures due to the complexity of the human brain, providing personalized solutions and overcoming limitations of manual operations [7] Development History - The introduction of ROSA in 2014 marked the beginning of neurosurgical robots in China, but adoption was slow due to operational complexities. Recent years have seen a surge in new entrants and technological advancements [8][9] Key Considerations for BCI Implantation - Successful BCI implantation requires careful consideration of imaging analysis, multimodal image fusion, robotic navigation, and automated execution mechanisms [10] Competitive Advantages - Tuodao Medical's comprehensive product line and integration of advanced technologies like force feedback provide a competitive edge in the neurosurgery and BCI sectors [15] Future Outlook - The BCI industry is expected to grow rapidly, with automation being a prerequisite for mass production. The company is closely monitoring market trends and planning accordingly [16][17] - The timeline for widespread adoption remains uncertain, but the company is preparing for future developments in automated surgical procedures [16][17]

Core Insights - The image-guided radiation therapy (IGRT) is a cornerstone of precise radiation treatment, significantly enhancing treatment accuracy and safety through advanced imaging and processing technologies [1][6][12] - The market size for IGRT in China is projected to reach 302 million yuan in 2024, reflecting a year-on-year growth of 58.12%, driven by the rising cancer incidence and increasing demand for precision medicine [1][6][7] - The global IGRT market is expected to grow to 329 million USD in 2024, with a year-on-year increase of 44.93% [6][7] Industry Overview - IGRT utilizes medical imaging technology to monitor and adjust the position of tumors and surrounding tissues in real-time during radiation therapy, ensuring precision and safety [2][3] - The technology integrates high-performance computers and imaging devices (such as X-ray, CT, MRI, and ultrasound) to obtain real-time patient positioning information [2][3] - IGRT can dynamically correct positioning errors and organ displacements, particularly effective in treating head and neck tumors, pediatric tumors, and complex anatomical structures [2][3] Market Size - The IGRT market in China is experiencing significant growth, with a projected market size of 302 million yuan in 2024, up from previous years [1][6][7] - The increase in cancer incidence, with 4.958 million new cases reported in 2023 (a 2.76% increase), is a key driver for the demand for IGRT systems [5][6] Industry Chain - The upstream of the IGRT industry includes high-precision detectors, special alloy materials, optical materials, electronic components, X-ray sources, and software algorithms [3][4] - The midstream involves the research and manufacturing of IGRT devices, while the downstream consists of various medical institutions, including public hospitals and private oncology specialty hospitals [3][4] Key Companies - Shanghai United Imaging Healthcare Co., Ltd. is a leading player in the high-end medical equipment sector in China, achieving significant advancements in IGRT [8][9] - Jiangsu Ruil Medical Technology Co., Ltd. focuses on developing and selling proprietary IGRT technologies and has received multiple certifications for its products [11][12] Industry Development Trends - Future IGRT systems will focus on higher precision and intelligence, integrating AI and big data for enhanced image recognition and processing capabilities [12][13] - The demand for IGRT systems is expected to expand into grassroots medical institutions, supported by government investments and increasing domestic production capabilities [13][14] - Personalized treatment and precision medicine will become more prevalent, with IGRT systems incorporating genetic information and multidisciplinary team approaches for treatment planning [15]